AI-powered wargaming shows why lower reactogenicity may not disrupt the shingles vaccine market without proof of better completion.
Keep the protection. Remove the pain.
That has become one of the most attractive ideas in shingles vaccine development. The logic appears straightforward. If a next-generation shingles vaccine can maintain the protection of today’s standard of care while reducing the severe short-term reactions that discourage some patients from returning for a second dose, adoption should follow.
Most analyses stop there. Our simulation did not. We ran an AI-powered competitive wargame to test whether lower reactogenicity could overcome an incumbent protected by efficacy, durability, reimbursement continuity, pharmacy workflow advantages, and stakeholder trust.
The answer was more complicated than expected.
What AI-Powered Wargaming Revealed About Next-Generation Shingles Vaccines
The simulation indicated that the primary constraint on a lower-reactogenicity shingles vaccine is not efficacy, immunogenicity, or even reactogenicity itself. The primary constraint is proving that lower reactogenicity increases second-dose completion in a way that matters to regulators, payers, pharmacies, and public-health stakeholders.
Across multiple scenarios, stakeholders viewed improved tolerability as a positive attribute. However, they also required evidence that fewer short-term reactions could lead to higher second-dose completion, better population-level outcomes, and measurable economic value.
This became the central strategic challenge for the entrant. Tolerability can create interest, but interest does not automatically create access.
The commercial logic behind lower reactogenicity is clear. The incumbent vaccine delivers strong protection and long-term durability, but is associated with reactogenicity that can disrupt daily activities for some recipients. A challenger that preserves protection while reducing those reactions addresses a meaningful patient concern.
From a product-development perspective, the strategy makes sense. From a stakeholder perspective, the picture is more complex.
Regulators do not approve vaccines simply because they are preferred. Payers do not grant access only because they are more comfortable. Public-health decision makers do not issue recommendations only because they improve convenience.
Each stakeholder evaluates value differently, and those competing perspectives reshape the market.
Why the Shingles Vaccine Access Moat Is Difficult to Break
Most competitive analyses focus on efficacy, safety, or reactogenicity. The simulation suggested that another factor may be equally important: access.
The incumbent benefits from years of clinical experience, recommendation continuity, established reimbursement pathways, pharmacy familiarity, durability evidence, and operational simplicity. Together, these advantages create a strong access position.
This finding appeared consistently across the simulation variants. The entrant repeatedly improved its credibility, and stakeholders responded positively to active-controlled Phase III designs, patient-reported outcomes, durability follow-up, and efforts to show that lower reactogenicity could improve second-dose completion.
However, credibility and access did not move at the same pace. Evidence opened doors, but it did not automatically open the market.
This distinction became particularly important when the entrant attempted to translate lower reactogenicity into a payer value story. Stakeholders acknowledged the logic: if fewer adverse reactions lead to higher completion rates, the resulting health outcomes could create meaningful value.
However, stakeholders wanted proof rather than projections. The simulation did not reject the hypothesis, but it made clear that the hypothesis depends on evidence.
Why Lower Reactogenicity Struggles Against Incumbent Advantages
The simulation revealed five recurring barriers that repeatedly limited the entrant’s ability to convert better tolerability into market share.
The Completion Trap
Stakeholders consistently redirected the conversation from patient experience to measurable evidence of behavioral change.
The critical question was not whether patients preferred fewer side effects, but whether fewer side effects resulted in more patients completing the vaccine series.
The Evidence Gap
The assumption that fewer side effects improve adherence appears intuitive. The simulation showed that intuition is not enough.
Regulators, payers, public-health stakeholders, and KOLs all demanded evidence that tolerability improvements translate into real-world behavior change.
Regulatory Asymmetry
Entrants face a different standard than incumbents.
Promising tolerability signals generated interest but did not reduce expectations around durability, safety characterization, manufacturing consistency, or evidence maturity.
Lower reactogenicity was viewed as a supporting attribute, not a substitute for traditional evidence requirements.
Payer Inertia
Payers viewed tolerability as a convenience benefit unless it could be linked directly to economic outcomes. Completion rates, healthcare utilization, and total cost of care mattered. Patient preference alone did not.
As a result, the incumbent’s contracting position remained resilient throughout the simulation.
Pharmacy Workflow Reality
Reduced counseling burden created genuine interest, particularly in scenarios where patient concerns about post-vaccination reactions became more prominent. However, operational simplicity remained equally important.
The simulation repeatedly showed that workflow advantages can outweigh biological differentiation.
How FDA, ACIP, Payers, Pharmacies, and KOLs Shape Shingles Vaccine Adoption
The simulation reinforced that next-generation shingles vaccine adoption is ultimately a stakeholder problem rather than only a product problem.
FDA stakeholders focused on efficacy, durability, safety characterization, manufacturing quality, and evidence maturity. Lower reactogenicity created interest, but did not reduce evidentiary expectations.
ACIP and public-health decision makers evaluated population-level outcomes rather than product-level preferences. Completion improvements mattered only when implementation benefits could be demonstrated at scale.
Payers were one of the most influential groups in the simulation. Their central question remained consistent: what changes economically if patients experience fewer side effects? Until that answer becomes measurable, incumbent economics remain difficult to challenge.
Pharmacies operated at the intersection of patient experience and operational reality. Reduced counseling burden was valuable, but workflow simplicity, stocking practices, and reimbursement continuity remained equally important.
KOLs acted as scientific gatekeepers. Their support depended less on tolerability itself and more on evidence that tolerability improvements translate into meaningful outcomes.
The Key Question for Next-Generation Shingles Vaccines
The simulation repeatedly returned to the same strategic uncertainty: how much improvement in second-dose completion would be needed to change stakeholder behavior?
The relevant threshold is not simply enough improvement to generate interest or improve patient experience. It is enough to influence payer decisions, public-health recommendations, pharmacy behavior, and switching from an incumbent with established evidence, entrenched access, and years of stakeholder confidence.
The simulation showed that lower reactogenicity can open conversations and generate interest among patients, pharmacists, and clinical stakeholders. What remains unproven is whether that interest translates into action.
Until stakeholders see compelling evidence that improved tolerability produces meaningful gains in completion rates, population-level outcomes, and economic value, the incumbent’s advantages are likely to remain intact.
For next-generation shingles vaccines, the key question is whether a better patient experience can be translated into a measurable public-health benefit.
The Future of Next-Generation Shingles Vaccine Competition
The industry increasingly assumes that reducing short-term side effects creates a natural competitive advantage. The simulation challenged that assumption.
The future competitive battleground is not reactogenicity alone. It is the ability to prove that lower reactogenicity improves completion rates in a way that matters to stakeholders.
The challenge is not proving that patients prefer fewer side effects. The challenge is proving that those preferences change behavior, that behavior changes outcomes, and that those outcomes create measurable value.
That is the difference between a better vaccine experience and a market-disrupting strategy.
AI-powered wargaming helped expose that distinction before clinical programs, access strategies, and launch plans become locked in.
The central lesson was simple: tolerability can open the conversation, but evidence of improved completion is what changes decisions.
What Strategic Assumption Is Your Team Making?
AI-powered wargaming helps teams test vaccine strategy assumptions before they become clinical programs, launch plans, or market-access commitments.
Explore more AI-powered wargaming scenarios to see how regulators, payers, competitors, KOLs, and other stakeholders reshape outcomes across biopharma markets.
Facing a high-stakes strategic decision?
LucidWargames can build a custom AI-powered wargame around your product, market, or competitive challenge.
Contact us at info@lqventures.com.